Straits Times Index
3,380.84 -5.09 (-0.15%) S&P 500
4,141.44 +30.36 (+0.74%) Dow
34,001.82 +110.80 (+0.33%) Nasdaq
12,020.18 +132.73 (+1.12%) BTC-USD
23,101.12 +77.21 (+0.34%) CMC Crypto 200
531.99 +6.04 (+1.15%)
Baxter International Inc. (BAX)
| Previous close | 45.16 |
| Open | 44.87 |
| Bid | 45.53 x 1000 |
| Ask | 45.54 x 900 |
| Day's range | 44.54 - 45.83 |
| 52-week range | 43.25 - 89.70 |
| Volume | |
| Avg. volume | 5,465,686 |
| Market cap | 22.895B |
| Beta (5Y monthly) | 0.59 |
| PE ratio (TTM) | 22.71 |
| EPS (TTM) | 2.00 |
| Earnings date | 09 Feb 2023 |
| Forward dividend & yield | 1.16 (2.54%) |
| Ex-dividend date | 01 Dec 2022 |
| 1y target est | 58.01 |
- Zacks
Quipt Home Medical Corp. (QIPT) to Report Q1 Results: Wall Street Expects Earnings Growth
Quipt Home Medical Corp. (QIPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Earnings Preview: Baxter International (BAX) Q4 Earnings Expected to Decline
Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire
Miromatrix and Baxter Announce Collaborative Research Agreement Aiming to Advance Care for Patients with Acute Liver Failure
EDEN PRAIRIE, Minn. & DEERFIELD, Ill., February 01, 2023--Miromatrix Medical Inc. (NASDAQ: MIRO) and Baxter International Inc. (NYSE:BAX) today announced a collaborative research agreement to help support additional treatment options for patients with acute liver failure (ALF) in need of organ support therapies. As part of the collaboration, Miromatrix has created a new liver therapy called miroliverELAP that combines a Miromatrix single-use bioengineered liver with Baxter’s PrisMax system. Miro
